Home / Journals / Journal of Endocrinology, Diabetes and Metabolic Complications / Articles In Press

Review Article

Silent Autoimmunity: Understanding the Gradual Impact of Hashimoto’s Thyroiditis on Metabolic Health

Authors: Pourkazemi G11 Zuccoli E11 Hooshmand D11 Apovian H11 Giacona S11 Tinsley W11

*Corresponding Author: Zuccoli E, Department of Endocrinology, Kosovo

Copyright: © 2026 Zuccoli E, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Zuccoli E (2026). Silent Autoimmunity: Understanding the Gradual Impact of Hashimoto’s Thyroiditis on Metabolic Health V1(3)

Received: Jan 22, 2026

Accepted: Jan 29, 2026

Published: Feb 05, 2026

Keywords: immunological mechanisms, acute thyroid disorders, chronic autoimmune condition, myxedema coma, autoimmune disorder, thyroid-stimulating hormone

Abstract

Hashimoto’s Thyroiditis is a chronic autoimmune condition that progressively impairs thyroid function, often developing unnoticed until significant hormonal imbalance occurs. Unlike acute thyroid disorders, its subtle onset and fluctuating symptoms make early diagnosis challenging. This article explores the immunological mechanisms, clinical presentation, diagnostic pathways, and long-term management strategies of Hashimoto’s Thyroiditis. By emphasizing early detection and personalized treatment, it highlights how timely intervention can mitigate complications and improve quality of life.

Introduction

Hashimoto’s Thyroiditis is one of the most common causes of hypothyroidism worldwide. First described by Japanese physician Hakaru Hashimoto in 1912, the disease arises when the immune system mistakenly attacks the thyroid gland. Over time, this leads to chronic inflammation and reduced production of thyroid hormones, which are essential for regulating metabolism, energy levels, and overall physiological balance.

Pathophysiology

The hallmark of Hashimoto’s Thyroiditis is autoimmune-mediated destruction of thyroid tissue. The body produces antibodies such as:

  • Anti-thyroid peroxidase (anti-TPO) antibodies

  • Anti-thyroglobulin antibodies

These antibodies target thyroid cells, gradually impairing hormone synthesis. This process ultimately leads to Hypothyroidism, characterized by decreased levels of thyroxine (T4) and triiodothyronine (T3), along with elevated thyroid-stimulating hormone (TSH).

Clinical Manifestations

Symptoms often develop slowly and may vary widely among individuals. Common features include:

  • Persistent fatigue and sluggishness

  • Weight gain despite unchanged diet

  • Cold intolerance

  • Dry skin and hair thinning

  • Depression or memory issues

  • Menstrual irregularities in women

In some cases, the thyroid gland becomes enlarged, resulting in a goiter.

Diagnosis

Diagnosis of Hashimoto’s Thyroiditis typically involves a combination of clinical evaluation and laboratory tests:

  • Elevated TSH levels

  • Low T3 and T4 levels

  • Presence of anti-TPO antibodies

Imaging techniques like thyroid ultrasound may reveal a heterogeneous or shrunken gland, supporting the diagnosis.

Management and Treatment

Although there is no cure for Hashimoto’s Thyroiditis, effective management focuses on hormone replacement and symptom control. The standard treatment involves:

  • Administration of Levothyroxine to restore normal hormone levels

  • Regular monitoring of thyroid function tests

  • Lifestyle adjustments, including balanced nutrition and stress management

Patients often require lifelong therapy, with dosage adjustments based on periodic evaluations.

Conclusion
Hashimoto’s Thyroiditis is a complex autoimmune disorder with far-reaching effects on the body’s metabolic processes. Despite its chronic nature, proper diagnosis and individualized treatment enable most patients to lead healthy lives. Increased awareness and routine screening, especially in high-risk populations, are key to managing this often-overlooked condition effectively.

References

  1. Benvenga, S.; Antonelli, A. Inositol(s) in thyroid function, growth and autoimmunity. Rev. Endocr. Metab. Disord. 2016, 17, 471–484.
  2. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions; Version 6.4 (Updated August 2023); Cochrane: London, UK, 2023.
  3. Knapp, G.; Hartung, J. Improved tests for a random effects meta-regression with a single covariate. Stat. Med. 2003, 22, 2693–2710.
  4. Jung, H.Y.; Jeon, Y.; Kim, Y.S.; Kang, S.-W.; Yang, C.W.; Kim, N. et al. Sex disparities in mortality among patients with kidney failure receiving dialysis. Sci. Rep. 2022, 12, 18555.
  5. Andreatta, M.; Carmona, S.J. UCell: Robust and Scalable Single-Cell Gene Signature Scoring. Comput. Struct. Biotechnol. J. 2021, 19, 3796–3798.
  6. Wichman, J.; Winther, K.H.; Bonnema, S.J.; Hegedüs, L. Selenium Supplementation Significantly Reduces Thyroid Autoantibody Levels in Patients with Chronic Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. Thyroid 2016, 26, 1681–1692.